Division of Circassia Pharmaceuticals PLC
Latest From Aerocrine AB
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Therapeutic Areas
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Circassia Pharmaceuticals PLC
- Senior Management
Marshall Woodworth, CFO
Kathleen Rickard, MD, CMO
Mats Carlson, VP, Global Business
Anders Murman, Chief Technical Officer
- Contact Info
Phone: (46) 8 629 0780
Solna, SE-169 67
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.